Main > > >GASTROENTEROLOGY.

---

Acid Reflux Symptoms Relief.
Over-The-Counter Device.
Upper Esophageal Sphincter (UES) Assist
Device.
USA Clearance Date: 2018. 05.01.
(*) Company : Somna Therapeutics LLC.
TradeMark: Reza Band
Web-Site : www.rezaband.com
UpDate: 2018. 05.02.




Barretts Esophagus>TREAT.: CryoTherapy
(C)
USA Approval Date: 2017. 07.17.
(*) Company; TradeMark & Web-Site
Available on Request.
UpDate: 2017. 11.27




Barretts Esophagus>TREAT.: PhotoTherapy>Sensitizer.
Generic Name: Porfimer Na Inj.
USA Initial Approval Year: 1995.
(*) Company : Pinnacle Biologics Inc.
TradeMark: PHOTOFRIN.
Web-Site : pinnaclebiologics.com/wp-

content/uploads/2012/12/USPI.pdf
UpDate: 2017. 11.27.




Bleeding (Non-Variceal). Control.
Endoscopy Hemostasis.
USA Approval Date: 2018. 05.07.
(*) Company : Cook Medical.
TradeMark: HemoSpray.
Web-Site : hemospray.cookmedical.com
UpDate: 2018. 05.08.




Crohns Disease (CD). Diag.:
Panel is a series of CE MARK IVD kits that help physicians identify patients who have Crohn s Disease and which of the patients are at higher risk for bowel damage and surgery. These patients can be candidates for “top down” therapy with biologics. Is the most validated and cost-effective serological panel to aid in the deferential diagnosis of IBD vs. non-IBD and for CD vs. UC, as well as for predicting the probability of Crohn s Disease progression
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 08.27.




Crohns Disease (CD). Treat.:
InflixiMAb-axxq BioSimilar.
USA Approval Date: 2019. 12.06.
(*) Company; TradeMark & Web-Site Avai-
lable on Request.
UpDate: 2020. 04.11.




Colitis. Ulcerative Colitis. TREAT.:
Budesonide ER Tablets. BRAND.
NL Approval Date : 2013. 01.31.
USA Approval Date: 2013. 01.14.
(*) Companies; Patents; TradeMarks &
Web-Site Available on Request.
UpDate: 2018. 04.25.




Colitis. Ulcerative Colitis. TREAT.:
Budesonide ER Tablets. GENERIC.
USA Launch Date: 2018. 07.09.
(*) Company: Teva Pharma.
UpDate: 2018. 07.10.




Colitis. Ulcerative Colitis. TREAT.:
InflixiMAb-axxq BioSimilar.
USA Approval Date: 2019. 12.06.
(*) Company; TradeMark & Web-Site Avai-
lable on Request.
UpDate: 2020. 04.11.




Colitis. Ulcerative Colitis. TREAT.: InflixiMAb dyyb BioSimilar.
CA Approval Date: 2016. 06.14.
USA Approval Date: 2016. 04.05.
USA Launch Date: 2016. 10.17.
Approved in AU, BR, CA, EU, USA.
(*) Company & TradeMarks Available on
Request.
UpDate: 2017. 12.15.




Colitis. Ulcerative Colitis. TREAT.: InflixiMAb qbtx BioSimilar.
chimeric human-murine MAb against tumor necrosis factor
USA Approval Date: 2017. 12.13.
(*) Company & TradeMark Available on
Request.
UpDate: 2017. 12.15.




Colitis. Ulcerative Colitis. TREAT.:
Mesalamine Delayed-Release Tablets.
Generic.
USA Launch Date: 2018. 12.17.
(*) Company: Mylan.
UpDate: 2018. 12.18.




Colitis. Ulcerative Colitis. TREAT.:
Tofacitinib.
USA Approval Date: 2018. 05.30.
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2018. 05.31.




Constipation. TREAT.: Lubiprostone Capsules.
chronic idiopathic constipation (CIC) in adults.
chloride channel activator which increases fluid secretion and motility of the intestine, facilitating passage of stool.
USA Approval Date: 2006. 01.31.
(*) Company: Sucampo Pharma. (ACQ. By Mallinckrodt PLC.)
USA Patent Expiration Date: 2012. 08.06.
TradeMark: Amitiza.
Web-Site : www.amitiza.com
UpDate: 2017. 12.28.




Constipation. TREAT.: Plecanatide 3 mg Tablet.
chronic idiopathic constipation (CIC) in adults.
guanylate cyclase-C (GC-C) agonist.
USA Approval Date: 2017. 01.19.
(*) Company; Patent; TradeMark & Web-Site Available on
Request
UpDate: 2018. 01.26.




Crohns Disease. TREAT.: Budesonide Capsules. Generic.
USA Launch Date: 2018. 01.18.
(*) Company: Amneal Pharma.
UpDate: 2018. 01.19.




Crohns Disease. TREAT.: InflixiMAb dyyb BioSimilar.
USA Availability: 2016. 10.17.
Approved in: AU, BR, CA, EU, USA.
(*) Company & TradeMarks Available on
Request.
UpDate: 2017. 12.15.




Crohns Disease. TREAT.: InflixiMAb qbtx BioSimilar.
chimeric human-murine MAb against tumor necrosis factor
USA Approval Date: 2017. 12.13.
(*) Company & TradeMark Available on
Request.
UpDate: 2017. 12.15.




Diarrhea. TREAT.: Racecadotril Oral
Availability>
>Asia>CN; IN & TH
>EU>CZ; DE; ES; FI; FR; IT; PL; PT; RU
& UK
>South America>Most
(*) Company; Patents; TradeMarks & Web-
Site Available on Request.
UpDate: 2021. 03.22.




Fecal InContinence (FI). TREAT.: rechar-
geable Sacral NeuroModulation (SNM) Sys-
tem.
1st Generation (1G): Recharge Device for
1 Hour Every 2
Weeks.
2nd Generation (2G): Recharge Device for
1 Hour Once a Month
External Trial System>
>Trial the therapy and assess symptom
improvement prior to having the patient
undergo the full implant procedure.
>CA Approval Date: 2018. 11.07.
>EU Approval Date: 2018. 07.09.
AU 1G Approval : 2018. 01.08.
CA 1G Approval : 2016. 12.
EU 1G Approval : 2016. 06.
USA 1G Approval: 2019. 09.09.
USA 2G Approval: 2020. 04.14.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 05.04.




GastroESophageal Reflux Disease (GERD)
Treat.: Vonoprazan Fumarate.
JP Launch Date: 2015. 02.26.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 04.17.




GastroIntestinal Dysmotility (GID).
Treat.: Electrical Stimulation to Eso-phagus.
EU Approval Date: 2018. 11.20.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.25.




H. Pylori Infection. DIAG.:
- H. PYLORI QUIK CHEK™:
detects H. pylori in 30 minutes
- H. PYLORI CHEK™:
96-well plate format diagnostic for
laboratories testing large numbers of
specimens and can be performed with or
without automation in one hour.
USA Approval Date: 2018. 08.21.
(*) Company : TECHLAB Inc.
Web-Site : www.techlab.com
UpDate: 2018. 08.22.




Inflammatory Bowel Disease (IBD). DIAG.:
Fully Automated, Random Access Calprotectin Test.
CIA: Chemiluminescent Immuno Assays.
USA Approval Date: 2018. 01.03.
(*) Company : Inova Diagnostics.
TradeMark: QUANTA Flash® (CIA)
Web-Site : www.inovadx.com/store/categories/quanta-
flashr-cia/1
UpDate: 2018. 01.04.




Irritable Bowel Syndrome with
Constipation. (IBS-C). TREAT.:
Linaclotide Capsules.
Guanylate Cyclase‐C Agonist.
CN Approval Date : 2019. 01.15.
JP Approval Date : 2016. 12.19.
USA Approval Date: 2012. 08.30.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 01.16.




Irritable Bowel Syndrome with Constipation. (IBS-C). TREAT.:
Plecanatide 3 mg Tablets.
guanylate cyclase-C (GC-C) agonist.
USA Approval Date: 2018. 01.25.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 01.26.




Surgery. Sealant. Algae-Derived Alginate Sealant.
While sutures and staples are the standard of care for surgical wound closure, they are incapable of water-tight or air-tight sealing of wounds. Bowel content leakage from GI incisions is still one of the complications most dreaded by GI surgeons, due to its potential fatal implications.
In addition to and in correlation with the significant morbidity and mortality, GI anastomotic leaks are associated with a 56% increase in the length of stay and with an additional cost of $28,000 per patient on average.
EU Approval Date: 2018. 01.04.
(*) Company; Patent; TradeMark & Web-Sites Available on
Request.
UpDate: 2018. 01.05.




Ulcerative Proctitis. TREAT.:
Mesalamine Rectal Suppository. Generic.
USA Launch Date: 2018. 12.17.
(*) Company: Mylan
UpDate: 2018. 12.18.


>GASTROENTEROLOGY.'s products
This section has no products